Regeneron Pharmaceuticals
REGN
633 hedge funds and large institutions have $20.4B invested in Regeneron Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 251 increasing their positions, 214 reducing their positions, and 79 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 251 | Existing positions reduced: 214
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.36% less ownership
Funds ownership: 68.66% → 68.3% (-0.36%)
4% less funds holding
Funds holding: 658 → 633 (-25)
11% less call options, than puts
Call options by funds: $497M | Put options by funds: $560M
12% less capital invested
Capital invested by funds: $23.1B → $20.4B (-$2.7B)
29% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 79
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$177M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$92.2M |
| 3 |
Harris Associates
Chicago,
Illinois
|
+$67.1M |
| 4 |
BlackRock
New York
|
+$63.3M |
| 5 |
Two Sigma Investments
New York
|
+$37.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$137M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$126M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$124M |
| 4 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$66.7M |
| 5 |
Goldman Sachs
New York
|
-$48.3M |
REGN Hedge Fund Activity: Q3 2019 in Review
633 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2019, worth a combined $20.4B — down 12% from $23.1B a quarter earlier.
Sellers outnumbered buyers: 79 funds closed out of REGN and 56 opened new positions — a net loss of 23 holders — while 214 trimmed existing stakes and 251 added.
The largest buyer was AllianceBernstein, adding an estimated $177M. The largest seller was Fidelity Investments, cutting an estimated $137M.
- 633 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2019, down from 658 in Q2 2019.
- Funds reported $20.4B of Regeneron Pharmaceuticals stock for Q3 2019, down 12% quarter-over-quarter.
- 56 funds opened new Regeneron Pharmaceuticals positions in Q3 2019 and 79 closed out, a net change of -23 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2019 was AllianceBernstein, an estimated $177M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2019 was Fidelity Investments, an estimated $137M sold.
Based on aggregated 13F filings for Q3 2019.